$-0.22 EPS Expected for Fate Therapeutics, Inc. (FATE); Vocera Communications (VCRA)’s Sentiment Is 1.39

April 29, 2018 - By Peter Erickson

Vocera Communications, Inc. (NYSE:VCRA) Logo

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $-0.22 EPS on May, 21.They anticipate $0.02 EPS change or 8.33% from last quarter’s $-0.24 EPS. After having $-0.29 EPS previously, Fate Therapeutics, Inc.’s analysts see -24.14% EPS growth. The stock decreased 3.53% or $0.41 during the last trading session, reaching $11.21. About 631,289 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 112.01% since April 29, 2017 and is uptrending. It has outperformed by 100.46% the S&P500.

Vocera Communications Inc (VCRA) investors sentiment increased to 1.39 in Q4 2017. It’s up 0.01, from 1.38 in 2017Q3. The ratio is more positive, as 68 active investment managers increased and opened new holdings, while 49 decreased and sold their positions in Vocera Communications Inc. The active investment managers in our database reported: 28.81 million shares, up from 28.22 million shares in 2017Q3. Also, the number of active investment managers holding Vocera Communications Inc in top ten holdings decreased from 2 to 1 for a decrease of 1. Sold All: 10 Reduced: 39 Increased: 45 New Position: 23.

Investors sentiment decreased to 1.58 in 2017 Q4. Its down 0.21, from 1.79 in 2017Q3. It dropped, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 17 funds opened positions while 24 raised stakes. 32.27 million shares or 31.43% more from 24.55 million shares in 2017Q3 were reported. Raymond James And Associate invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Wells Fargo & Com Mn stated it has 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Morgan Stanley holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 519,062 shares. Panagora Asset Management holds 23,463 shares. Bridgeway Mngmt invested 0.02% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Parametric Port Associates Ltd Co, Washington-based fund reported 12,034 shares. Virtu Financial Lc holds 0.01% or 18,251 shares in its portfolio. Vanguard Grp Inc accumulated 1.46 million shares. Meeder Asset Mgmt Incorporated, Ohio-based fund reported 217 shares. Manufacturers Life Ins The holds 33,337 shares. First Manhattan reported 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Fincl Bank Of America De stated it has 6,013 shares or 0% of all its holdings. Moreover, Voya Inv Mgmt Llc has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 21,533 shares. Bnp Paribas Arbitrage holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 9,423 shares. 683 Lc has 853,800 shares.

Among 10 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Fate Therapeutics had 21 analyst reports since October 6, 2015 according to SRatingsIntel. On Tuesday, April 12 the stock rating was initiated by BMO Capital Markets with “Outperform”. BMO Capital Markets maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Wednesday, November 1 with “Buy” rating. H.C. Wainwright downgraded the stock to “Neutral” rating in Tuesday, March 6 report. The firm has “Buy” rating given on Wednesday, December 13 by H.C. Wainwright. The firm has “Buy” rating given on Friday, September 8 by Leerink Swann. The company was maintained on Tuesday, March 6 by BMO Capital Markets. Raymond James downgraded the shares of FATE in report on Tuesday, March 6 to “Hold” rating. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Buy” rating given on Thursday, March 15 by Piper Jaffray. The rating was maintained by H.C. Wainwright on Tuesday, March 20 with “Hold”. As per Tuesday, October 6, the company rating was initiated by Raymond James.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $591.58 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

The stock decreased 0.91% or $0.23 during the last trading session, reaching $25.17. About 293,265 shares traded or 20.31% up from the average. Vocera Communications, Inc. (VCRA) has declined 4.31% since April 29, 2017 and is downtrending. It has underperformed by 15.86% the S&P500.

Manatuck Hill Partners Llc holds 7.05% of its portfolio in Vocera Communications, Inc. for 447,200 shares. Awm Investment Company Inc. owns 398,834 shares or 2.34% of their US portfolio. Moreover, Brown Capital Management Llc has 1.59% invested in the company for 4.33 million shares. The Massachusetts-based Redwood Investments Llc has invested 1.36% in the stock. Conestoga Capital Advisors Llc, a Pennsylvania-based fund reported 1.08 million shares.

Vocera Communications, Inc. (NYSE:VCRA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts